Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 2/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20580635 | 1.00 | RAB9A (0.48) | RAB9ASMN1; SMN2NPC1MAPTKMT2A | |
| SCHEMBL19026343 | 0.97 | RAB9A (0.46) | RAB9ASMN1; SMN2NPC1MAPTKMT2A | |
| SCHEMBL19026344 | 0.97 | RAB9A (0.46) | RAB9ASMN1; SMN2NPC1MAPTKMT2A | |
| SCHEMBL14862556 | 0.89 | HTT (0.43) | RAB9ASMN1; SMN2NPC1MAPTKMT2A | |
| SCHEMBL17593772 | 0.89 | HTT (0.43) | RAB9ASMN1; SMN2NPC1MAPTKMT2A | |
| SCHEMBL25331076 | 0.86 | RAB9A (0.47) | RAB9ASMN1; SMN2NPC1MAPTKMT2A | |
| SCHEMBL23837192 | 0.84 | NPC1 (0.43) | RAB9ASMN1; SMN2NPC1MAPTKMT2A | |
| SCHEMBL22546078 | 0.84 | SMN1; SMN2 (0.43) | RAB9ASMN1; SMN2NPC1MAPTKMT2A | |
| SCHEMBL19026404 | 0.84 | TAAR1 (0.49) | RAB9ASMN1; SMN2NPC1MAPTTAAR1 | |
| SCHEMBL12475908 | 0.84 | TAAR1 (0.49) | RAB9ASMN1; SMN2NPC1MAPTTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024138128-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | GENENTECH, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-4271387-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCS CONTAINING AND USE THEREOF | Immunext, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT INC (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4136118-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Immunext, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022150637-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF | IMMUNEXT, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2021216913-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | CD47, CLTA, FCGR2A | RAB9A 1035/4885SMN1; SMN2 4605/4885NPC1 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.